Reliable, rapid, and high-throughput QC for IVT RNA vaccine development
In vitro-transcribed (IVT) RNA is a breakthrough method in vaccine development enabled by recent advances in mRNA research. The process begins with the isolation and genome sequencing of a pathogen of interest. A gene encoding a viral epitope mimicking the virus is produced synthetically and the RNA is transcribed in the lab. When introduced into the body, these synthetic RNA sequences instruct cells to produce a viral protein. The viral protein triggers an immune response which trains the body to combat the actual virus. To ensure high quality production of IVT RNA, implementing quality control (QC) at key steps throughput process development is critical. The Agilent Fragment Analyzer systems provide reliable nucleic acid analysis with flexible throughput options.